Search results for "Biologic therapies"
showing 7 items of 7 documents
Fine tuning the management of axial spondyloarthritis
2017
Updated recommendations for the management of axial spondyloarthritis provide a useful framework for physicians treating this disease. However, the guidance on use of biologic therapies and treat-to-target strategies seems to raise more questions than it answers.
Leishmaniasis and Biologic Therapies for Rheumatologic Diseases
2010
In his article in Seminars in Arthritis and Rheumatism,Furst (1) provides an accurate analysis of the infec-tions that are related to the use of biologic therapiesfor rheumatoid arthritis. We would like to addLeishma-niaspp to the list of the infectious agents that can causedisease during the course of biologic therapies.
Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes
2021
Funder: Global Initiative for Asthma
Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).
2016
Abstract Purpose Management of giant cell arteritis (GCA, Horton's disease) involves many uncertainties. This work was undertaken to establish French recommendations for GCA management. Methods Recommendations were developed by a multidisciplinary panel of 33 physicians, members of the French Study Group for Large Vessel Vasculitis (Groupe d’etude francais des arterites des gros vaisseaux [GEFA]). The topics to be addressed, selected from proposals by group members, were assigned to subgroups to summarize the available literature and draft recommendations. Following an iterative consensus-seeking process that yielded consensus recommendations, the degree of agreement among panel members was…
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
2016
Background: Data from routine clinical practice are needed to further define the efficacy and safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN). Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000. Patients were classified in three groups: group 1 = patients still taking ETN; group 2 = patients discontinued from ETN for any reasons; group 3 = patients lost to follow-up while receiving ETN. All three…
Timing of quality of life improvements in psoriatic patients treated with different systemic therapies
2019
Psoriasis impacts the quality of life (QoL) by disrupting overall health and social life. Thus, the use of a QoL evaluation item is crucial in assessing a therapeutic regimen. Also, faster improvements in QoL lead to better patient compliance, but very few studies compare psoriasis traditional and biologic therapies timing. To evaluate how much different systemic therapies improve disease severity and QoL, a retrospective analysis was performed on 56 patients. Subjects were administered different drugs and their vital statistics, psoriasis area severity index (PASI) and PSOdisk were collected at baseline and after 30 days. We found a moderate correlation between PASI and PSOdisk score with …